Alcista
Pfizer's stock hits new 52-week high at $29.09 amid positive developments
Este briefing aún no está disponible en este idioma — se muestra la versión en inglés.
Pfizer's stock reached a new 52-week high of $29.09, driven by a combination of positive factors. The company secured a favorable drug pricing agreement with the U.S. administration, reported stronger-than-expected second-quarter earnings, and resolved a significant legal settlement concerning one of its contraceptive products.
Puntos clave
- Pfizer's stock climbs to $29.09, a new 52-week high, following positive news.
- Company secures favorable drug pricing agreement with U.S. administration.
- Reports stronger-than-expected second-quarter earnings.
- Resolves significant legal settlement concerning contraceptive product.
Fuentes
- Pfizer Shares Hit New 52-Week High As Drug Pricing Deal, Earnings Beat And Settlement Lift Stock FurtherInternational Business Times · September 3, 2026
- Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue GuidanceNasdaq · August 4, 2026
- Pfizer Declares Third-Quarter 2026 DividendStockTitan · June 24, 2026
Generado por IA a partir de fuentes de noticias públicas. No es asesoramiento financiero.
